Sort   by:  
 Page size 
UnknownRandomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes.
Not available
S-EPMC4878053 | biostudies-literature
UnknownPhase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.
Not available
S-EPMC3675699 | biostudies-literature
UnknownValidation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes.
Not available
S-EPMC3438234 | biostudies-literature
UnknownClearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia.
Not available
S-EPMC6008108 | biostudies-literature
UnknownSignificant association between polymorphism of the erythropoietin gene promoter and myelodysplastic syndrome.
Not available
S-EPMC2992491 | biostudies-literature
UnknownMinimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia.
Not available
S-EPMC5779853 | biostudies-literature
UnknownDifferential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC).
Not available
S-EPMC5394924 | biostudies-literature
UnknownVenetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial.
Not available
S-EPMC8884174 | biostudies-literature
UnknownPredicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score system.
Not available
S-EPMC3913560 | biostudies-literature
UnknownClofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia.
Not available
S-EPMC4110914 | biostudies-literature
Sort   by:  
 Page size